Toggle menu


Start date:
March 2021
End date:
March 2022
Co-ordinated by:
Main trial site:
Royal Infirmary of Edinburgh

This trial is an open label two-arm randomised trial focused on identifying the best treatment for community acquired sepsis patients. We will be investigating the feasibility of delivering early intravenous fluid resuscitation by comparing 5% human albumin solution (HAS) to balanced crystalloid. Currently, balanced crystalloids are used as routine care and the first line therapy in the international sepsis guidelines, whereas HAS is the second line fluid therapy in septic shock. Although, studies are showing that HAS may have further potential benefits to patients with sepsis.

The study aims to recruit 300 patients who meet the following inclusion criteria:

  1. Clinically suspected or proven infection resulting in principal reason for acute illness;
  2. NEWS/NEWS2 score ≥5;
  3. Hospital presentation within last 12hrs;
  4. 4.Clinician decision has been made that immediate (within 1 hour of assessment) intravenous fluid resuscitation is needed; and;
  5. Ability to obtain informed consent.

Patients will be recruited in the Emergency Department and Medical and Surgical Assessment Units across UK NHS hospitals. The treatment will be administered within the first 6 hours of randomisation. Following this, patients will be reviewed for safety reasons and asked to complete a questionnaire in order to evaluate thier quality of life.

Research Team

Julia Grahamslaw

Lead Research Nurse

Miranda Odam

Research Nurse Manager

Rachel O'Brien

Lead Research Nurse

Polly Black

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Fiona McCurrach

Senior Research Nurse

Alison Grant

Senior Research Nurse

Alison Williams

Senior Research Nurse

Lisa Donald

Research Nurse

Emma Moatt

Research Project Manager

Nicholas Fethers

Research Administrator

Rebecca Trainer

Administrative Assistant

More EMERGE Trials

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more


Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more


Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions